| Name | Title | Contact Details |
|---|
Keir Surgical is a Vancouver, BC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Valeritas is committed to developing and commercializing innovative treatment solutions that contribute to clinical and humanistic outcomes for patients, with an initial focus on the treatment of Type 2 diabetes. Valeritas` portfolio is headlined by the V-Go® disposable insulin delivery device, which is being commercialized and reimbursed in a specialty pharmaceutical model and is distributed through retail pharmacy.
Fewer than 50% of Sleep Apnea patients stick with a CPAP solution – including us. So we decided to do something about it. Not sleeping sucks. Not sleeping and spending a fortune on CPAP devices that leak, fall off or leave marks on your face sucks even worse. That`s why we invented the DreamPort Sleep Solution – the world`s first-ever maskless CPAP device. The result is the smallest, lightest, most ergonomically accommodating CPAP solution on the market – a device that fits comfortably and doesn`t restrict your movement – enabling patients to get a better night`s sleep. Our goal is simple – to make the best bleeping CPAP products on the planet. We won`t stop until every sleep apnea patient is sleeping like a baby.
Avation Medical is an innovative advanced neuromodulation and digital health company pioneering closed-loop, patient-friendly, wearable neuromodulation therapies that deliver personalized therapy based on the patient`s own physiologic response. The Company`s intelligent wearable therapies objectively confirm activation of the target nerve and make neuromodulation technology accessible to millions of patients across a variety of clinical application by eliminating need for surgery, needles and permanent implants and shifting therapy into the home environment.
Driven to raise the standard of care and improve the lives of patients with brain tumors, a team of brain tumor specialists formed GT Medical Technologies. FDA-cleared GammaTile Therapy is a Surgically Targeted Radiation Therapy (STaRT) for patients undergoing brain tumor removal surgery of newly diagnosed malignant and recurrent brain tumors. This "one-and-done" treatment eliminates the need for one to six weeks of daily external beam radiation therapy, allowing patients to go about their daily lives without the burden of additional trips to the hospital or clinic for ongoing treatment. Since its full market release in the United States in March 2020, GammaTile has been offered in more than 95 hospitals, with more centers being added each month.